Clinical Trials Logo
  1. Home
  2. Chronic Granulomatous Disease
  3. NCT05915897
  4. Details
NCT05915897 Clinical Trial

Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)

Chronic Granulomatous Disease Clinical Trial

Official title:
Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT05915897
Other study ID # SAN-09687
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date May 23, 2023
Est. completion date March 25, 2024

Study information
Verified date April 2024
Source Sanguine Biosciences
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary study objective is to collect biospecimen samples (e.g., blood) from participants diagnosed with Chronic Granulomatous Disease (CGD). The biospecimens will be used to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.

Recruitment information / eligibility
Status Terminated
Enrollment 6
Est. completion date March 25, 2024
Est. primary completion date March 25, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - The participant is willing and able to provide written informed consent - The participant is willing and able to provide appropriate photo identification - Participants aged 18 to 85 - Participants have been diagnosed with Chronic Granulomatous Disease (CGD) - Subjects who have a confirmed p47phox CGD mutation or Subjects who have a confirmed X-linked CGD mutation Exclusion Criteria: - Participants who are pregnant or are nursing - Participants with a known history of HIV, hepatitis, or other infectious diseases - Participants who have taken an investigational product in the last 30 days - Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Specimen Donation
blood donation

Locations
Country Name City State
United States Sanguine BioSciences, Inc. Woburn Massachusetts

Sponsors (1)
Lead Sponsor Collaborator
Sanguine Biosciences

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Participants have been diagnosed with Chronic Granulomatous Disease (CGD) Participants have been diagnosed with Chronic Granulomatous Disease (CGD) 1 Year
See also
  Status Clinical Trial Phase
Withdrawn NCT03278912 - Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Completed NCT04136028 - IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease Early Phase 1
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Terminated NCT03080480 - Pioglitazone Therapy for Chronic Granulomatous Disease Phase 1/Phase 2
Terminated NCT00394316 - Gene Therapy for Chronic Granulomatous Disease Early Phase 1
Recruiting NCT03910452 - Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide Early Phase 1
Terminated NCT02282904 - Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide Phase 1/Phase 2
Terminated NCT02926963 - Generation of Powerful Biological Tools for Understanding the Pathophysiology of Chronic Granulomatous Disease. N/A
Completed NCT00006417 - Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease Phase 2
Completed NCT00368446 - Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT06162936 - Neutrophil Oxidative Burst in Early and Late Onset Pediatric Inflammatory Bowel Disease
Terminated NCT00325078 - Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease Phase 1/Phase 2
Completed NCT00001317 - A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood Phase 4
Completed NCT03548818 - Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease
Enrolling by invitation NCT06253507 - pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD) Phase 1/Phase 2
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Completed NCT00578643 - Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease Phase 2
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A